Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has submitted the cobas® EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration (FDA), as a companion ...
Quebec City, Canada. EXFO Inc. has unveiled its new NetBlazer v2 series, which the company calls the industry’s smallest portable 10G quad-port test solution designed to turn-up next-generation ...
Test and measurement products from Keysight aim to accelerate the development, implementation, and deployment of USB4 V2.0 compatible devices. The recently released USB4 V2.0 specification enables ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results